KR102924196B1 - Kcnq 강화제로서의 1-((2-(2,2,2-트리플루오로에톡시)피리딘-4-일)메틸)우레아 유도체 - Google Patents

Kcnq 강화제로서의 1-((2-(2,2,2-트리플루오로에톡시)피리딘-4-일)메틸)우레아 유도체

Info

Publication number
KR102924196B1
KR102924196B1 KR1020217028040A KR20217028040A KR102924196B1 KR 102924196 B1 KR102924196 B1 KR 102924196B1 KR 1020217028040 A KR1020217028040 A KR 1020217028040A KR 20217028040 A KR20217028040 A KR 20217028040A KR 102924196 B1 KR102924196 B1 KR 102924196B1
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
refers
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217028040A
Other languages
English (en)
Korean (ko)
Other versions
KR20210126040A (ko
Inventor
헬렌 제인 세케레스
앤드류 캐어윈 윌리엄스
마리아 앤 왓튼
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20210126040A publication Critical patent/KR20210126040A/ko
Application granted granted Critical
Publication of KR102924196B1 publication Critical patent/KR102924196B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217028040A 2019-02-06 2020-02-04 Kcnq 강화제로서의 1-((2-(2,2,2-트리플루오로에톡시)피리딘-4-일)메틸)우레아 유도체 Active KR102924196B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962801716P 2019-02-06 2019-02-06
US62/801,716 2019-02-06
US201962811038P 2019-02-27 2019-02-27
US62/811,038 2019-02-27
PCT/US2020/016499 WO2020163268A1 (en) 2019-02-06 2020-02-04 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators

Publications (2)

Publication Number Publication Date
KR20210126040A KR20210126040A (ko) 2021-10-19
KR102924196B1 true KR102924196B1 (ko) 2026-02-06

Family

ID=69743945

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028040A Active KR102924196B1 (ko) 2019-02-06 2020-02-04 Kcnq 강화제로서의 1-((2-(2,2,2-트리플루오로에톡시)피리딘-4-일)메틸)우레아 유도체

Country Status (23)

Country Link
US (4) US11208383B2 (cg-RX-API-DMAC10.html)
EP (1) EP3921030B1 (cg-RX-API-DMAC10.html)
JP (2) JP7451543B2 (cg-RX-API-DMAC10.html)
KR (1) KR102924196B1 (cg-RX-API-DMAC10.html)
CN (1) CN113692304B (cg-RX-API-DMAC10.html)
AU (1) AU2020218180B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021015544A2 (cg-RX-API-DMAC10.html)
DK (1) DK3921030T3 (cg-RX-API-DMAC10.html)
ES (1) ES2968807T3 (cg-RX-API-DMAC10.html)
FI (1) FI3921030T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240012T1 (cg-RX-API-DMAC10.html)
HU (1) HUE064734T2 (cg-RX-API-DMAC10.html)
IL (1) IL285113B2 (cg-RX-API-DMAC10.html)
LT (1) LT3921030T (cg-RX-API-DMAC10.html)
MX (1) MX2021009396A (cg-RX-API-DMAC10.html)
PL (1) PL3921030T3 (cg-RX-API-DMAC10.html)
PT (1) PT3921030T (cg-RX-API-DMAC10.html)
RS (1) RS65040B1 (cg-RX-API-DMAC10.html)
SA (1) SA521422733B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202108599SA (cg-RX-API-DMAC10.html)
SI (1) SI3921030T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400003T1 (cg-RX-API-DMAC10.html)
WO (1) WO2020163268A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7451543B2 (ja) * 2019-02-06 2024-03-18 イーライ リリー アンド カンパニー Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体
JP2023531500A (ja) 2020-06-25 2023-07-24 イドーシア ファーマシューティカルズ リミテッド シクロブチル－ウレア誘導体
WO2023054626A1 (ja) * 2021-09-30 2023-04-06 住友ファーマ株式会社 シクロプロパンアミド誘導体
AU2022390453B2 (en) * 2021-11-19 2026-03-19 Angelini Pharma S.P.A. Novel heteroaryl-urea compounds as kv7.2 inhibitors
JP2024540583A (ja) 2021-11-19 2024-10-31 アイカジェン・エルエルシー Ｋｖ７．２エンハンサーとしてのピリジン化合物
CN118510757A (zh) 2021-12-22 2024-08-16 伊卡根有限责任公司 环丙基化合物
WO2023158584A1 (en) 2022-02-15 2023-08-24 Icagen, Llc New bicyclopentane derivatives
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103709097A (zh) 2012-09-28 2014-04-09 中国科学院上海药物研究所 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用
WO2015130905A1 (en) 2014-02-27 2015-09-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0971892A1 (en) * 1997-03-25 2000-01-19 Astra Pharmaceuticals Limited Novel pyridine derivatives and pharmaceutical compositions containing them
CN100345823C (zh) * 2003-01-14 2007-10-31 赛特凯恩蒂克公司 化合物、组合物及方法
EP1737852A2 (en) 2004-04-13 2007-01-03 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
EP1781635B1 (en) * 2004-07-29 2012-06-13 Merck Sharp & Dohme Corp. Potassium channel inhibitors
WO2010036316A1 (en) * 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
CA2763786C (en) * 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
CA2828456C (en) * 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
BR112015022263B1 (pt) * 2013-03-15 2023-01-03 Deciphera Pharmaceuticals Llc N-acil-n-(piridin-2-il) uréias e análogos apresentando atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica
SG11201703284XA (en) * 2014-10-24 2017-06-29 Ono Pharmaceutical Co Kcnq2-5 channel activator
JP6943239B2 (ja) * 2016-04-22 2021-09-29 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル活性化剤
JP7451543B2 (ja) * 2019-02-06 2024-03-18 イーライ リリー アンド カンパニー Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103709097A (zh) 2012-09-28 2014-04-09 中国科学院上海药物研究所 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用
WO2015130905A1 (en) 2014-02-27 2015-09-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof

Also Published As

Publication number Publication date
RS65040B1 (sr) 2024-02-29
CN113692304B (zh) 2025-03-18
ES2968807T3 (es) 2024-05-14
WO2020163268A1 (en) 2020-08-13
CN113692304A (zh) 2021-11-23
IL285113B1 (en) 2025-06-01
US20240076269A1 (en) 2024-03-07
US11208383B2 (en) 2021-12-28
US11840516B2 (en) 2023-12-12
JP7451543B2 (ja) 2024-03-18
HUE064734T2 (hu) 2024-04-28
BR112021015544A2 (pt) 2021-10-26
HRP20240012T1 (hr) 2024-03-29
KR20210126040A (ko) 2021-10-19
CA3128975A1 (en) 2020-08-13
SA521422733B1 (ar) 2024-02-08
SG11202108599SA (en) 2021-09-29
AU2020218180A1 (en) 2021-08-19
US20250282725A1 (en) 2025-09-11
IL285113B2 (en) 2025-10-01
SI3921030T1 (sl) 2024-03-29
IL285113A (en) 2021-09-30
LT3921030T (lt) 2024-01-25
EP3921030A1 (en) 2021-12-15
MX2021009396A (es) 2021-09-10
PL3921030T3 (pl) 2024-05-06
SMT202400003T1 (it) 2024-03-13
US20220073464A1 (en) 2022-03-10
FI3921030T3 (fi) 2024-01-08
AU2020218180B2 (en) 2025-09-04
US12344584B2 (en) 2025-07-01
US20200247752A1 (en) 2020-08-06
DK3921030T3 (da) 2024-01-02
EP3921030B1 (en) 2023-10-11
PT3921030T (pt) 2024-01-12
JP2022519744A (ja) 2022-03-24
JP2024063191A (ja) 2024-05-10

Similar Documents

Publication Publication Date Title
US12344584B2 (en) KCNQ potentiators
EP4074703B1 (en) Pyridinyl-(aza)indolsulfonamides
AU2014333996B2 (en) Diazacarbazole derivatives as tau-pet-ligands
CN118221685A (zh) 作为kras g12d抑制剂的吲哚类化合物
KR20140019332A (ko) 베타-세크레타제(BACE)의 억제제로서 유용한 3,4-디하이드로-피롤로[1,2-a]피라진-1-일아민 유도체
RU2528333C2 (ru) Соединения и способы лечения боли и других заболеваний
WO2024169788A1 (zh) 稠环化合物及其用途
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
RU2790174C1 (ru) Производные 1-[[2-(2,2,2-трифторэтокси)пирид-4-ил]метил]мочевины в качестве потенциаторов kcnq
CA3128975C (en) 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators
HK40068179A (en) 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators
HK40068179B (en) 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators
US20250082786A1 (en) Fluorescent markers for neurofibrillar tangles and uses thereof
EP4301739B1 (en) Fpr2 (formyl peptide receptor 2) receptor agonists and their use in the treatment of the autism spectrum disorder
WO2025113692A1 (zh) 磺酰脲衍生物及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)